Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


02.04.2018

1 Am J Pathol
3 Anticancer Res
6 BJU Int
2 BMC Cancer
1 BMC Urol
1 Br J Cancer
1 Cancer
1 Cancer Res
1 Clin Cancer Res
2 Eur J Radiol
7 Eur Urol
1 Int J Cancer
3 Int J Urol
1 J Clin Oncol
1 J Magn Reson Imaging
3 J Nucl Med
2 J Urol
1 Magn Reson Med
1 Nat Rev Urol
1 PLoS One
1 Proc Natl Acad Sci U S A
6 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Pathol

  1. HAFFNER MC, Guner G, Taheri D, Netto GJ, et al
    Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
    Am J Pathol. 2018 Mar 22. pii: S0002-9440(17)31179.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. MASCAN B, Marignol L
    Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?
    Anticancer Res. 2018;38:1897-1902.
    PubMed     Text format     Abstract available

  3. UMEZAWA R, Inaba K, Nakamura S, Wakita A, et al
    Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Anticancer Res. 2018;38:2303-2309.
    PubMed     Text format     Abstract available

  4. TAKEZAWA Y, Izumi K, Machioka K, Iwamoto H, et al
    Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
    Anticancer Res. 2018;38:2045-2055.
    PubMed     Text format     Abstract available


    BJU Int

  5. ANSMANN L, Winter N, Ernstmann N, Heidenreich A, et al
    Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW).
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14215.
    PubMed     Text format     Abstract available

  6. VATANDOUST S, Kichenadasse G, O'Callaghan M, Vincent AD, et al
    Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14228.
    PubMed     Text format     Abstract available

  7. HARMOUCH SS, Berger AJ, Cole AP
    Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here?
    BJU Int. 2018;121:492-493.
    PubMed     Text format    

  8. STATTIN P, Sandin F, Loeb S, Robinson D, et al
    Public online reporting from a nationwide population-based clinical prostate cancer register.
    BJU Int. 2018 Mar 25. doi: 10.1111/bju.14213.
    PubMed     Text format     Abstract available

  9. CHEN R, Dong X, Gleave M
    Molecular Model for Neuroendocrine Prostate Cancer Progression.
    BJU Int. 2018 Mar 22. doi: 10.1111/bju.14207.
    PubMed     Text format     Abstract available

  10. KLOTZ L
    Prostate cancer prevention: proof is elusive.
    BJU Int. 2018;121:487-488.
    PubMed     Text format    


    BMC Cancer

  11. LANGIUS-EKLOF A, Crafoord MT, Christiansen M, Fjell M, et al
    Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cance
    BMC Cancer. 2017;17:466.
    PubMed     Text format     Abstract available

  12. GOLSTEIJN RHJ, Bolman C, Volders E, Peels DA, et al
    Development of a computer-tailored physical activity intervention for prostate and colorectal cancer patients and survivors: OncoActive.
    BMC Cancer. 2017;17:446.
    PubMed     Text format     Abstract available


    BMC Urol

  13. HE LY, Zhang M, Chen ZW, Yuan JL, et al
    Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.
    BMC Urol. 2018;18:23.
    PubMed     Text format     Abstract available


    Br J Cancer

  14. WALLIS CJD, Morton G, Herschorn S, Kodama RT, et al
    The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.
    Br J Cancer. 2018 Mar 29. pii: 10.1038/s41416-018-0071.
    PubMed     Text format     Abstract available


    Cancer

  15. GOLAN R, Bernstein AN, Gu X, Dinerman BA, et al
    Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31297.
    PubMed     Text format     Abstract available


    Cancer Res

  16. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  17. SCROGGINS B, Matsuo M, White A, Saito K, et al
    Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
    PubMed     Text format     Abstract available


    Eur J Radiol

  18. REISCHAUER C, Patzwahl R, Koh DM, Froehlich JM, et al
    Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study.
    Eur J Radiol. 2018;101:184-190.
    PubMed     Text format     Abstract available

  19. DI CAMPLI E, Delli Pizzi A, Seccia B, Cianci R, et al
    Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: Comparison between readers with different experience.
    Eur J Radiol. 2018;101:17-23.
    PubMed     Text format     Abstract available


    Eur Urol

  20. LAVORGNA G, Montorsi F, Salonia A
    Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Ther
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30181.
    PubMed     Text format    

  21. TOSOIAN JJ, Lotan TL
    The Androgen Signaling Axis and Risk Stratification for High-grade Prostate Cancer.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30188.
    PubMed     Text format    

  22. EKLUND M, Strom P, Nordstrom T, Gronberg H, et al
    Reply to Ola Bratt and Anna Ofverholm's Letter to the Editor re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. E
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30185.
    PubMed     Text format    

  23. KINSELLA N, Stattin P, Cahill D, Brown C, et al
    Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30176.
    PubMed     Text format     Abstract available

  24. BRATT O, Ofverholm A
    Re: Peter Strom, Tobias Nordstrom, Henrik Gronberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.0
    Eur Urol. 2018 Mar 26. pii: S0302-2838(18)30186.
    PubMed     Text format    

  25. VAN SOEST RJ, Tombal B, Lolkema MP, de Wit R, et al
    Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30178.
    PubMed     Text format    

  26. PANEBIANCO V, Barchetti G, Simone G, Del Monte M, et al
    Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Eur Urol. 2018 Mar 19. pii: S0302-2838(18)30183.
    PubMed     Text format     Abstract available


    Int J Cancer

  27. BELIC J, Graf R, Bauernhofer T, Cherkas Y, et al
    Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31397.
    PubMed     Text format     Abstract available


    Int J Urol

  28. ALBERTS AR, Roobol MJ
    Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2018;25:277.
    PubMed     Text format    

  29. OKIHARA K
    Editorial Comment to Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Mar 25. doi: 10.1111/iju.13570.
    PubMed     Text format    

  30. TILKI D, Pompe RS, Bandini M, Marchioni M, et al
    Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Mar 23. doi: 10.1111/iju.13535.
    PubMed     Text format     Abstract available


    J Clin Oncol

  31. SZMULEWITZ RZ, Peer CJ, Ibraheem A, Martinez E, et al
    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2018 Mar 28:JCO2017764381. doi: 10.1200/JCO.2017.76.4381.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  32. GAUR S, Harmon S, Mehralivand S, Bednarova S, et al
    Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    J Magn Reson Imaging. 2018 Mar 31. doi: 10.1002/jmri.26025.
    PubMed     Text format     Abstract available


    J Nucl Med

  33. LUCKERATH K, Stuparu AD, Wei L, Kim W, et al
    Detection threshold and reproducibility of (68)Ga-PSMA11 PET/CT in a mouse model of prostate cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.118.207704. doi: 10.2967/jnumed.118.207704.
    PubMed     Text format     Abstract available

  34. ZETTLITZ KA, Tsai WK, Knowles SM, Kobayashi N, et al
    Dual-modality immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using an anti-prostate cancer stem cell antigen (PSCA) cys-diabody.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207332. doi: 10.2967/jnumed.117.207332.
    PubMed     Text format     Abstract available

  35. HARMON SA STEPHANIE., Bergvall E, Mena E, Shih JH, et al
    A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207373. doi: 10.2967/jnumed.117.207373.
    PubMed     Text format     Abstract available


    J Urol

  36. WEI C, Li C, Szewczyk-Bieda M, Upreti D, et al
    Performance characteristics of transrectal shear wave elastography (SWE) imaging in the evaluation of clinically localised prostate cancer: a prospective study.
    J Urol. 2018 Mar 29. pii: S0022-5347(18)42856-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  37. SHAH N, Ioffe V
    Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    J Urol. 2018 Mar 26. pii: S0022-5347(18)42402.
    PubMed     Text format    


    Magn Reson Med

  38. CHEN HY, Larson PEZ, Gordon JW, Bok RA, et al
    Technique development of 3D dynamic CS-EPSI for hyperpolarized (13) C pyruvate MR molecular imaging of human prostate cancer.
    Magn Reson Med. 2018 Mar 25. doi: 10.1002/mrm.27179.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  39. KELSEY R
    Prostate cancer: Solo PSA test does not lower mortality.
    Nat Rev Urol. 2018 Mar 27. pii: nrurol.2018.41. doi: 10.1038/nrurol.2018.
    PubMed     Text format    


    PLoS One

  40. SHIN H, Park YH, Kim YG, Lee JY, et al
    Aqueous two-phase system to isolate extracellular vesicles from urine for prostate cancer diagnosis.
    PLoS One. 2018;13:e0194818.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  41. SEHRAWAT A, Gao L, Wang Y, Bankhead A 3rd, et al
    LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Proc Natl Acad Sci U S A. 2018 Mar 26. pii: 1719168115.
    PubMed     Text format     Abstract available


    Prostate

  42. LINXWEILER J, Korbel C, Muller A, Hammer M, et al
    A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
    PubMed     Text format     Abstract available

  43. GAO X, Mao YH, Xiao C, Li K, et al
    Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
    Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
    PubMed     Text format     Abstract available

  44. BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
    Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
    PubMed     Text format     Abstract available

  45. BRENNEN WN, Isaacs JT
    The what, when, and why of human prostate cancer xenografts.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
    PubMed     Text format     Abstract available

  46. AKINBOYE ES, Rogers OC, Isaacs JT
    2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
    PubMed     Text format     Abstract available

  47. CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
    Exercise and prostate cancer: From basic science to clinical applications.
    Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
    PubMed     Text format     Abstract available


    Urology

  48. KESCH C, Black PC
    Filling a True Unmet Need: a New Therapy for Non-Metastatic Castrate Resistant Prostate Cancer. Commentary on: Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer.
    Urology. 2018 Mar 26. pii: S0090-4295(18)30260.
    PubMed     Text format    

  49. LIU JS, Hofer MD, Sheth KR, Cordon BH, et al
    Improving Outcomes of Bulbomembranous Urethroplasty for Radiation-Induced Urethral Strictures in Post-Urolume Era.
    Urology. 2016 Aug 2. pii: S0090-4295(16)30459.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: